Krystal Biotech Inc. (KRYS) witnessed a remarkable 5.61% surge in its stock price during the pre-market trading session on Thursday, February 20th, 2025. This significant upward movement was fueled by the company's robust financial performance in the fourth quarter of 2024 and an optimistic outlook from a prominent analyst.

Krystal Biotech reported stellar earnings for Q4 2024 and the full year, driven by the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). The company achieved net income per share of $3.12 for the full year 2024, a substantial increase from $0.40 in the previous year, marking six consecutive quarters of positive earnings growth.

In Q4 2024, Krystal Biotech generated net VYJUVEK revenue of $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% during the quarter, showcasing its operational efficiency and strong financial position, with $749.6 million in total cash and investments at the end of Q4 2024.

In addition to the impressive financial results, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.